The combined benefits of a mineralocorticoid receptor antagonist (MRA), an angiotensin receptor-neprilysin inhibitor (ARNI), and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with ...
The clinical benefits of semaglutide (Wegovy; Novo Nordisk) in patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF) don’t appear to be influenced by left ...
Long-term oral β-blocker therapy, including bisoprolol, metoprolol, and carvedilol, reduces the composite endpoint of all-cause death, new myocardial infarction, or heart failure by 25% in ...
Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Finerenone improved outcomes in patients with heart ...
Elevated baseline LDH levels predict worse clinical outcomes in heart failure with reduced ejection fraction and modestly ...
Dapagliflozin significantly reduced the risk of cardiovascular (CV) death or worsening of heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFpEF), according to ...
Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results